Cancer research

Cancer research

Prioritizing Bevacizumab Plus Chemotherapy in PD-L1-Negative Lung Adenocarcinoma Patients

Research conducted at the Affiliated Cancer Hospital of Zhengzhou University has highlighted the effectiveness of bevacizumab plus chemotherapy as a first-line treatment option for programmed death-ligand 1 (PD-L1) negative lung adenocarcinoma (LUAD) patients without common gene-alterations. The study, published in Frontiers in Oncology, analyzed the clinical effectiveness and safety of

Cancer research

Substantial Improvement in Cancer Detection and Positive Predictive Value: PATHFINDER 2 Study Yields Encouraging Results

The GRAIL, Inc. has announced positive top-line performance and safety results from the PATHFINDER 2 study, a registrational study evaluating the safety and performance of the Galleri multi-cancer early detection (MCED) test. The study, initiated in 2021, has enrolled 25,578 participants and demonstrated substantial improvement in cancer detection and